BBOT vs RVMD
BBOT: A clinical-stage oncology firm developing next-generation small-molecule inhibitors to target RAS and PI3K-driven cancers through monotherapy and combination strategies. RVMD: Revolution Medicines is a precision oncology company developing targeted therapies to treat RAS-addicted cancers through its proprietary research platform.
Side-by-side fundamentals
| Metric | BBOT | RVMD | Edge |
|---|---|---|---|
| Price as of 2026-10-20 close | $2.72 | $196.55 | |
| Market cap | $218M | $42.1B | |
| ROE FY2025, SEC XBRL | -32.6% | -69.3% | BBOT higher |
| ROA FY2025, SEC XBRL | -29.9% | -48.0% | BBOT higher |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 0.43 | 1.05 | |
| 1-year return as of 2026-10-20 close | -75.8% | +263.9% | RVMD higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.